Article Details

Gilead's Q4 Revenue Slips on Weaker HIV and COVID-19 Sales, Amid Phase III Flops

Retrieved on: 2024-02-07 18:50:37

Tags for this article:

Click the tags to see associated articles and topics

Gilead's Q4 Revenue Slips on Weaker HIV and COVID-19 Sales, Amid Phase III Flops. View article details on hiswai:

Excerpt

Veklury (remdesivir), Gilead's intravenous antiviral coronavirus treatment, only brought in $720 million during the fourth quarter, representing a ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo